Brodalumab治疗中重度斑块状银屑病的真实世界24周回顾性研究
结果显示治疗4周后PASI即显著下降,并持续至第24周;生活质量与患者满意度显著提升,治疗中断率11.5%。
要点
- Brodalumab在真实世界中快速且持续改善中重度斑块状银屑病严重程度。
- 既往抗IL-17治疗失败的患者仍可从Brodalumab治疗中获益。
- 心血管代谢合并症多及既往治疗多与PASI 90达标负相关。
核心结论
- Brodalumab在真实世界中对中重度斑块状银屑病有效且安全,包括抗IL-17治疗失败的患者。
主要发现
- 治疗4周后平均PASI即显著下降,第12周和第24周进一步下降(均P < 0.0001 vs. 基线)。
- 心血管代谢合并症数量较多及既往治疗次数较多与所有评估时点PASI 90达标呈负相关。
- 生活质量和患者满意度在治疗期间显著提升(分别P < 0.0001和P < 0.01 vs. 基线)。
- 9例(11.5%)患者中断治疗,原因包括不良事件(n = 4)、疗效不足(n = 3)、失访(n = 1)和手术(n = 1)。
临床怎么用
- Brodalumab可用于中重度斑块状银屑病的真实世界治疗,包括既往抗IL-17治疗失败者。
- 对合并症多、既往治疗史复杂的患者,需关注PASI 90达标可能较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited. OBJECTIVES: To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. METHODS: This observational, retrospective study enrolled adult patients (≥18 years) with moderate-to-severe plaque-type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded. RESULTS: Seventy-eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P < 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio-experienced patients, including those who had failed on anti-interleukin (IL)-17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P < 0.0001 and P < 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow-up (n = 1) and surgical procedure (n = 1). CONCLUSIONS: Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies.
引用
- Fargnoli MC, Esposito M, Dapavo P, et al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2020. PMID: 32916767. doi:10.1111/jdv.16931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。